Deng Yu-Xiang, Zhao Yu-Jie, Nong Qiao-Hong, Qiu Hong-Mei, Guo Qiao-Li, Hu Hui
Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518000, People's Republic of China.
Department of Radiotherapy, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518000, People's Republic of China.
Breast Cancer (Dove Med Press). 2024 Jul 23;16:393-402. doi: 10.2147/BCTT.S468239. eCollection 2024.
The immune system appears to play a crucial role in how breast cancer responds to chemotherapy. In this study, we investigated a peripheral marker of immune and inflammation named the neutrophil to albumin ratio (NAR) to explore its potential relationship with pathological complete response (pCR) in locally advanced breast cancer patients who underwent neoadjuvant chemotherapy (NAC).
We conducted a retrospective analysis of 212 consecutive breast cancer patients who received NAC. The NAR was calculated by examining the complete blood cell count and albumin level in peripheral blood before starting NAC. Through ROC curve analysis, we determined the optimal cutoff value for NAR as 0.0877. We used Pearson's chi-square test or Fisher's exact test to evaluate the relationship between NAR and pCR, as well as other clinical and pathological characteristics. Logistic regression models were employed for univariate and multivariate analyses.
The results of both univariate and multivariate logistic regression analyses showed that NAR was associated with tumor pathological regression. The NAR high group had a higher pCR rate compared to the NAR low group (OR 3.127 [95% CI 1.545-6.328]; p = 0.002).
According to this study, it was observed that patients with breast cancer who had high levels of NAR were more likely to achieve pCR when undergoing NAC.
免疫系统似乎在乳腺癌对化疗的反应中起着关键作用。在本研究中，我们调查了一种名为中性粒细胞与白蛋白比值（NAR）的免疫和炎症外周标志物，以探讨其与接受新辅助化疗（NAC）的局部晚期乳腺癌患者病理完全缓解（pCR）的潜在关系。
我们对212例连续接受NAC的乳腺癌患者进行了回顾性分析。通过在开始NAC前检测外周血全血细胞计数和白蛋白水平来计算NAR。通过ROC曲线分析，我们确定NAR的最佳截断值为0.0877。我们使用Pearson卡方检验或Fisher精确检验来评估NAR与pCR以及其他临床和病理特征之间的关系。采用逻辑回归模型进行单因素和多因素分析。
单因素和多因素逻辑回归分析结果均显示，NAR与肿瘤病理退缩相关。NAR高分组的pCR率高于NAR低分组（OR 3.127 [95% CI 1.545 - 6.328]；p = 0.002）。
根据本研究，观察到NAR水平高的乳腺癌患者在接受NAC时更有可能实现pCR。
